PD-L1 – Medxy AI

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY 08/11/2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Gastroenterology news Oncology

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY 06/27/2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and improving antitumor immunity.

Hematology-Oncology news Pediatrics

Checkpoint Inhibition Is Reshaping Pediatric Lymphoma Care, Led by Breakthroughs in Hodgkin Lymphoma and Expanding into PD-L1–Positive Non-Hodgkin Subtypes

By MedXY 06/06/2026

Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.

news Oncology Respiratory

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.